In a recent study published in PLoS Computational Biology, researchers used mathematical modelling to evaluate whether prioritizing older individuals for coronavirus disease 2019 (COVID-19) booster vaccinations consistently leads to optimal public health outcomes across diverse socio-economic settings.
In the early stages of the COVID-19 pandemic, non-pharmaceutical interventions (NPIs) were crucial in reducing transmission and protecting healthcare systems.
The introduction of vaccines, such as those from Pfizer-BioNTech, Oxford-AstraZeneca, and Moderna, significantly altered the pandemic’s trajectory by reducing severe cases and relaxing NPIs.
However, immunity from these vaccines wanes over time, necessitating booster vaccinations, especially with emerging variants.
Further research is needed to refine booster vaccination strategies to address varying population structures and socio-economic contexts globally, ensuring the most effective public health outcomes.
About the study
The study extends a previously published age-structured compartmental model of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) transmission and vaccination.
This deterministic model, governed by ordinary differential equations, divides individuals into compartments based on age, current infection status, and immune status before any infection.
The model includes 16 age groups, with individuals classified as Susceptible, Exposed, Infectious (symptomatic or asymptomatic), or Recovered.
To more accurately represent the time spent in the exposed class, the model employs gamma distributions, which provide a realistic representation of epidemiological periods.
The model also tracks immune status, categorizing individuals into groups such as Vaccinated, Boosted, Partially Waned, Fully Waned, and Unvaccinated, reflecting their infection and vaccination history.
The effectiveness of vaccination is incorporated into the model, accounting for reduced risks of infection, symptoms, hospitalization, and death.
Using this model, the study examines the impacts of six different age-based booster vaccination strategies across eight countries. Strategy 1 prioritizes the oldest individuals first, while Strategy 6 explores vaccinating those with the most contacts to provide indirect protection to the elderly.
Strategies 2-5 test variations of these approaches, generally focusing on prioritizing older individuals for booster vaccination. The analysis assumes limited vaccine availability, with a 10% population coverage baseline and a 90% maximum uptake per age group.
Study results
The population’s age structure varies significantly across countries, with high-income countries generally having a larger proportion of older individuals compared to low-income countries.
This demographic difference influences the distribution of booster vaccines under different vaccination strategies. In the UK, for instance, strategies 1-4 that prioritize older individuals for booster vaccination result in a substantial number of individuals aged 50-74 receiving vaccines. However, the oldest individuals (75+) may not be fully covered due to the limited vaccine supply.
On the other hand, Strategies focused on vaccinating younger individuals, particularly those aged 20-49, who typically have more contacts and, therefore, could potentially contribute to indirect protection of older populations.
However, the age distribution of vaccinated individuals under each strategy varies between countries. For example, in Sierra Leone, where the proportion of older individuals is relatively small, Strategies 1-4 effectively vaccinate almost all older individuals, leading to identical outcomes for these strategies.
This contrasts with the situation in the UK, where a larger elderly population means that not all older individuals can be vaccinated under these strategies due to vaccine constraints.
When considering the impact of these strategies on public health outcomes during a wave of infections caused by a novel SARS-CoV-2 variant, the model projections indicated that Strategy 1 consistently resulted in the fewest deaths across all countries analyzed.
This outcome is particularly evident in high-income countries, where a large proportion of older individuals contribute to a higher projected number of deaths if they are not prioritized for booster vaccination.
In contrast, in countries like Sierra Leone, the small number of older individuals allows nearly all of them to receive booster vaccines under Strategy 1, leading to fewer deaths overall.
The analysis also examined the projected Years of Life Lost (YLL), which accounts for the number of deaths and the ages at which they occur.
While it might be expected that vaccinating younger individuals could reduce YLL, the model consistently showed that Strategy 1, which prioritizes the oldest individuals, was optimal in minimizing YLL. This is due to the higher risk of severe outcomes and mortality associated with SARS-CoV-2 infection in older populations.
Sensitivity analyses further supported these findings, showing that Strategy 1 led to fewer deaths and YLL under various assumptions, including different levels of vaccine availability, uptake rates, and timing of booster administration.
Even when the outbreak began 150 days after booster vaccines were administered, resulting in some immunity waning, Strategy 1 remained the most effective approach in reducing deaths and YLL.
Conclusions
To summarize, future SARS-CoV-2 transmission will be influenced by novel variants, booster vaccinations, and immunity dynamics. Unlike the pandemic’s early stages, many individuals globally are now infected or vaccinated, impacting immunity and transmission.
In this evolving scenario, it is essential to reassess the effectiveness of past interventions and explore new strategies.
This study evaluated different age-based booster vaccination strategies and found that prioritizing older individuals consistently leads to better public health outcomes, regardless of varying population structures.
- Bouros I, Hill EM, Keeling MJ, et al. (2024) Prioritizing older individuals for COVID-19 booster vaccination leads to optimal public health outcomes in a range of socio-economic settings. PLoS Comput Biol. doi:https://doi.org/10.1371/journal. pcbi.1012309. https://journals.plos.org/ploscompbiol/article?
News
World First: Stem Cell Transplant Restores Vision in Multiple People
A radical stem cell transplant has significantly improved the blurry vision of three people with severe damage to their cornea. The clinical trial, which took place in Japan, is the first of its kind in the world, [...]
Clinical Trial: Mushroom Supplement May Halt Prostate Cancer Growth
The bidirectional research examines both laboratory findings and human clinical trial data, revealing that the medicinal use of white button mushrooms reduces the type of cells that suppress the immune system and facilitate the [...]
Scientists propose drug-free method to combat antibiotic-resistant bacteria
Recent estimates indicate that deadly antibiotic-resistant infections will rapidly escalate over the next quarter century. More than 1 million people died from drug-resistant infections each year from 1990 to 2021, a recent study reported, with [...]
New study shows how salmonella tricks gut defenses to cause infection
A new UC Davis Health study has uncovered how Salmonella bacteria, a major cause of food poisoning, can invade the gut even when protective bacteria are present. The research, published in the Proceedings of the National Academy [...]
Chlamydia vaccine shows early promise in mice
An experimental vaccine has shown promise in protecting against the sexually transmitted disease chlamydia, researchers report. Lab mice given the vaccine were able to rapidly clear subsequent chlamydia infections, and were less likely to [...]
Contradictory Discovery: Our Innate Immune System May Fuel Cancer Development
MSK researchers discovered that the innate immune system’s chronic activation due to issues in the Mre11 complex can lead to cancer, highlighting new therapeutic targets. In addition to defending against pathogens, the body’s innate [...]
New study links circadian gene variants to winter depression
Findings suggest that PER3 gene variants prevent adrenal adaptation to winter daylight, leading to serotonin disruption and depression-like behaviors. A recent study in Nature Metabolism used humanized mice with modified PERIOD3 gene variants (P415A and H417R) [...]
Quantum Leap for MRI: Atomic Sensors Unlock New Imaging Potential
New atomic sensor technology enhances MRI quality control by tracking hyperpolarized molecules in real-time, with potential benefits for various scientific fields. Magnetic resonance imaging (MRI) is a fundamental tool in modern medicine, offering detailed [...]
MethylGPT unlocks DNA secrets for age and disease prediction
By harnessing advanced AI, MethylGPT decodes DNA methylation with unprecedented accuracy, offering new paths for age prediction, disease diagnosis, and personalized health interventions. In a recent study posted to the bioRxiv preprint* server, researchers developed a [...]
“Astonishing” – Scientists Unveil First Blueprint of the Most Complex Molecular Machine in Human Biology
Researchers unveil the inner mechanisms of the most intricate and complex molecular machine in human biology. Scientists at the Centre for Genomic Regulation (CRG) in Barcelona have developed the first comprehensive blueprint of the [...]
Breakthrough research reveals how to target malignant DNA in aggressive cancers
Scientists have discovered a way to target elusive circular fragments of DNA that drive the survival of some of the most aggressive cancers, paving the way for future treatments. In three groundbreaking papers published [...]
How bacteria trigger colon cancer
In a recent study published in Nature, scientists used murine models to investigate how certain bacteria, such as Escherichia coli strains that contain a polyketide synthase (pks) island encoding enzymes that produce colibactin genotoxin, could increase the [...]
Nanoparticles designed to trap and neutralise large amounts of SARS-CoV2
(Nanowerk News) Researchers from the IBB-UAB have developed a new class of nanostructures capable of trapping and neutralising large quantities of the SARS-CoV2 virus particles, both in liquid solutions and on the surface of [...]
Nanodiscs: What Are They and How Are They Shaping the Future of Medicine?
Nanodiscs are synthetic phospholipid particles with a distinct morphology and size that enhance their efficiency in drug delivery applications.1 First developed by Sligar et al. in the early 2000s, these model membrane systems measure around 10 [...]
New Discovery Reveals How Ovarian Cancer Starves Immune Cells
Researchers discovered that ovarian tumors hinder T cells’ energy supply by trapping a key protein, blocking lipid uptake. A new approach to reprogram T cells could enhance immunotherapy for aggressive cancers. Researchers at Weill Cornell [...]
Innovative Drug-Design Strategies to Overcome Antibacterial Resistance
Antibacterial resistance occurs when antibiotics fail to treat bacterial infections. This incidence is considered one of the top global health threats, stemming from the misuse or overuse of antibiotics in humans and animals.1 The [...]
